[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100054117":3},{"organization":4,"armGroups":7,"interventions":10,"overallOfficials":12,"centralContacts":16,"locations":10,"responsibleParty":22,"collaborators":10,"id":24,"slug":25,"hasResults":26,"nctId":27,"briefTitle":28,"officialTitle":29,"acronym":30,"eligibilityCriteria":31,"healthyVolunteers":26,"sex":32,"minAge":33,"maxAge":34,"enrollmentInfo":35,"targetDuration":10,"studyType":38,"phases":10,"briefSummary":39,"conditions":40,"keywords":42,"overallStatus":48,"whyStopped":10,"lastUpdateSubmitDate":49,"lastUpdatePostDateStruct":50,"startDateStruct":53,"completionDateStruct":55,"leadSponsor":57,"locationsCount":10},{"fullName":5,"class":6},"Novartis","INDUSTRY",[8],{"label":9,"type":10,"description":11,"interventionNames":10},"Iptacopan Cohort",null,"Adult patients with C3G who received iptacopan through an EAP in Spain.",[13],{"name":14,"affiliation":14,"role":15},"Novartis Pharmaceuticals","STUDY_DIRECTOR",[17,21],{"name":14,"role":18,"phone":19,"phoneExt":10,"email":20},"CONTACT","+41613241111","novartis.email@novartis.com",{"name":14,"role":18,"phone":10,"phoneExt":10,"email":10},{"type":23,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100054117","a-study-of-complement-3-glomerulopathy-c3g-patients-treated-with-iptacopan-through-an-early-access-program-in-spain-100054117",false,"NCT07598448","A Study of Complement 3 Glomerulopathy (C3G) Patients Treated With Iptacopan Through an Early Access Program in Spain","Clinical Experience With Iptacopan in Adult Patients With Complement 3 Glomerulopathy (C3G): A Multicenter, Observational, Retrospective Study of Patients Treated Through an Early Access Program in Spain","ROUTE-C3G","Inclusion criteria:\n\n1. Adult patients (≥18 years).\n2. Biopsy-confirmed C3G.\n3. Patients who have received at least one dose of iptacopan through an EAP from October 2020 to June 2025.\n\nExclusion criteria:\n\n1\\. Patients treated with iptacopan through an EAP for indications other than C3G.","ALL","18 Years","100 Years",{"count":36,"type":37},35,"ESTIMATED","OBSERVATIONAL","This study aims to characterize the patient profiles and the clinical experience of iptacopan treatment in adult patients with C3G treated through an early access program (EAP) in Spain.",[41],"Complement 3 Glomerulopathy",[41,43,44,45,46,47],"C3G","Iptacopan","Factor B inhibition","Alternative Complement Pathway","Early Access Program","NOT_YET_RECRUITING","2026-07-09",{"date":51,"type":52},"2026-07-13","ACTUAL",{"date":54,"type":37},"2026-08-23",{"date":56,"type":37},"2026-12-15",{"name":14,"class":6}]